GRAIL (NASDAQ:GRAL) CEO Robert Ragusa Sells 7,461 Shares

GRAIL, Inc. (NASDAQ:GRAL) CEO Robert Ragusa sold 7,461 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $47.89, for a total value of $357,307.29. Following the sale, the chief executive officer owned 642,084 shares of the company’s stock, valued at approximately $30,749,402.76. This trade represents a 1.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

GRAIL Trading Down 0.8%

GRAL stock traded down $0.41 during trading on Monday, reaching $49.82. The stock had a trading volume of 1,587,964 shares, compared to its average volume of 2,112,505. The firm has a market cap of $1.94 billion, a PE ratio of -4.46 and a beta of 5.21. The stock’s 50 day moving average is $88.14 and its two-hundred day moving average is $77.99. GRAIL, Inc. has a 52 week low of $20.44 and a 52 week high of $118.84.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. The firm had revenue of $43.60 million during the quarter, compared to analyst estimates of $43.33 million. On average, research analysts anticipate that GRAIL, Inc. will post -15.15 EPS for the current year.

Institutional Trading of GRAIL

Several institutional investors have recently made changes to their positions in the business. WIM INVESTMENT MANAGEMENT Ltd grew its stake in GRAIL by 200.0% during the third quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 63,000 shares of the company’s stock valued at $3,725,000 after acquiring an additional 42,000 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of GRAIL by 159.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,120 shares of the company’s stock valued at $12,188,000 after purchasing an additional 126,576 shares during the last quarter. Caxton Associates LLP bought a new position in shares of GRAIL during the 2nd quarter valued at about $3,320,000. NWF Advisory Services Inc. purchased a new position in shares of GRAIL during the second quarter valued at about $1,062,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of GRAIL in the third quarter worth about $885,000.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on GRAL shares. Morgan Stanley decreased their price target on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. TD Cowen initiated coverage on GRAIL in a research report on Thursday, February 19th. They issued a “hold” rating and a $114.00 price target for the company. Guggenheim lifted their price objective on GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Canaccord Genuity Group reduced their target price on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a report on Friday, February 20th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $90.17.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.